US00547W2089 - Common Stock - After market: 0.185 0 (-0.16%)
NASDAQ:ADMP (12/6/2022, 7:19:55 PM)-0.01 (-3.74%)
|GICS Sector||Health Care|
|Earnings (Last)||11-14 2022-11-14/amc||Earnings (Next)||03-29 2023-03-29|
|Ins Owners||0.67%||Inst Owners||8.57%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The firm is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, which is used in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more; and SYMJEPI (epinephrine) Injection 0.15mg, which is used in the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates include ZIMHI (naloxone) Injection, which is used for the treatment of opioid overdose; and Tempol (APC-400), an investigational drug, which is used in the fields of COVID-19 infection, asthma, respiratory syncytial virus infection, and influenza infection. The company also has a microbicide product candidate, named C31G.
ADAMIS PHARMACEUTICALS CORP
Suite 310, 11455 El Camino Real
San Diego CALIFORNIA 92130
CEO: Dennis J. Carlo
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ...
We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning!
Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!
It's time for another dive into the biggest pre-market stock movers as we check out what's behind shares moving on Wednesday!
Here you can normally see the latest stock twits on ADMP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.